Source comparison
BPC-157 Chronic Pain Research Mechanism: Clinical Study Comparison
Sciatic nerve crush (rats) Axonal regrowth + remyelination via NGF/BDNF upregulation 14–21 days Gabapentin blocks pain signals but doesn't restore nerve function. BPC-157 regenerated damaged axons Structural repair outperforms symptom suppression for neuropath
This comparison does not assign a generated winner or score.
- Sciatic nerve crush (rats)
- Axonal regrowth + remyelination via NGF/BDNF upregulation
- 14–21 days
- Gabapentin blocks pain signals but doesn't restore nerve function. BPC-157 regenerated damaged axons
- Structural repair outperforms symptom suppression for neuropathic pain long-term
- Chemically induced colitis (rats)
- Substance P reduction + mucosal barrier restoration
- 7–10 days
- NSAIDs reduce inflammation but delay mucosal healing. BPC-157 accelerated both
- Dual action (anti-inflammatory + regenerative) makes it distinct from conventional treatments
- Tendon injury (rats)
- FAK-mediated collagen synthesis + angiogenesis
- 10–14 days
- Corticosteroids suppress inflammation but inhibit collagen formation. BPC-157 enhanced it
- Tissue regeneration approach addresses the root cause rather than masking pain
- Adjuvant-induced arthritis (rats)
- Reduction in inflammatory cytokines (TNF-α, IL-6) + cartilage preservation
- 14–28 days
- Methotrexate suppresses immune response systemically. BPC-157 acted locally at joint tissue
- Localized anti-inflammatory effect with fewer systemic side effects observed
- The comparison table underscores a consistent theme: BPC-157 chronic pain research demonstrates mechanisms that rebuild damaged structures rather than blocking pain pathways downstream.